Schiff base complexes of copper and zinc as potential anti-colitic compounds

Elaine M. Conner, John Reglinski, W. Ewen Smith, I. Jack Zeitlin

Research output: Contribution to journalArticle

5 Citations (Scopus)
33 Downloads (Pure)


The design, synthesis and activity of polymodal compounds for the treatment of inflammatory bowel disease are reported. The compounds, being based on a metal-Schiff base motif, are designed to degrade during intestinal transit to release the bioactive components in the gut. The compounds have been developed sequential with the biomodal compounds combining copper or zinc with a salicylaldehyde adduct. These compounds were tested in a formalin induced colonic inflammation model in BK:A mice. From these studies a trimodal compound based on a zinc Schiff base analogue of Sulfosalazine were designed. This was tested against a trinitrobenzenesulfonic acid (TNB) induced colitic model in Wistar rats. The use of two models allows us to test our compounds in both an acute and a chronic model. The trimodal compound reported is observed to provide anticolitic properties in the chronic TNB induced colitis model commensurate with that of SASP. However, the design of trimodal compound still has the capacity for further development. This the platform reported may offer a route into compounds which can markedly outperform the anti-colitic properties of SASP.
Original languageEnglish
Pages (from-to)423-439
Number of pages17
Issue number3
Early online date19 Apr 2017
Publication statusPublished - 30 Jun 2017


  • inflammatory bowel disease
  • metal-Schiff base
  • colitis

Fingerprint Dive into the research topics of 'Schiff base complexes of copper and zinc as potential anti-colitic compounds'. Together they form a unique fingerprint.

Cite this